GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (FRA:BIO) » Definitions » Cyclically Adjusted FCF per Share

Biotest AG (FRA:BIO) Cyclically Adjusted FCF per Share : €0.27 (As of Jun. 2024)


View and export this data going back to 1987. Start your Free Trial

What is Biotest AG Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Biotest AG's adjusted free cash flow per share for the three months ended in Jun. 2024 was €1.445. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.27 for the trailing ten years ended in Jun. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -46.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -47.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Biotest AG was -29.40% per year. The lowest was -61.10% per year. And the median was -40.35% per year.

As of today (2024-09-24), Biotest AG's current stock price is €41.20. Biotest AG's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 was €0.27. Biotest AG's Cyclically Adjusted Price-to-FCF of today is 152.59.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Biotest AG was 4300.00. The lowest was 20.60. And the median was 73.38.


Biotest AG Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Biotest AG's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG Cyclically Adjusted FCF per Share Chart

Biotest AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.38 0.24 0.04 0.06

Biotest AG Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.11 -0.07 0.06 0.07 0.27

Competitive Comparison of Biotest AG's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Biotest AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotest AG's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biotest AG's Cyclically Adjusted Price-to-FCF falls into.



Biotest AG Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biotest AG's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=1.445/125.8815*125.8815
=1.445

Current CPI (Jun. 2024) = 125.8815.

Biotest AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 -0.112 99.823 -0.141
201412 0.700 99.543 0.885
201503 0.330 99.717 0.417
201506 0.465 100.417 0.583
201509 0.076 100.417 0.095
201512 0.099 99.717 0.125
201603 0.508 100.017 0.639
201606 0.743 100.717 0.929
201609 -0.066 101.017 -0.082
201612 0.480 101.217 0.597
201703 -0.315 101.417 -0.391
201706 -0.268 102.117 -0.330
201709 0.352 102.717 0.431
201712 1.100 102.617 1.349
201803 -0.789 102.917 -0.965
201806 -0.515 104.017 -0.623
201809 -0.250 104.718 -0.301
201812 0.303 104.217 0.366
201903 -0.263 104.217 -0.318
201906 -0.007 105.718 -0.008
201909 -0.618 106.018 -0.734
201912 -0.042 105.818 -0.050
202003 -0.272 105.718 -0.324
202006 -0.372 106.618 -0.439
202009 -0.349 105.818 -0.415
202012 0.513 105.518 0.612
202103 -0.404 107.518 -0.473
202106 0.070 108.486 0.081
202109 0.414 109.435 0.476
202112 0.729 110.384 0.831
202203 0.531 113.968 0.587
202206 -0.471 115.760 -0.512
202209 -0.484 118.818 -0.513
202212 -0.587 119.345 -0.619
202303 -0.969 122.402 -0.997
202306 -0.929 123.140 -0.950
202309 0.147 124.195 0.149
202312 1.675 123.773 1.704
202403 -0.291 125.038 -0.293
202406 1.445 125.882 1.445

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Biotest AG  (FRA:BIO) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Biotest AG's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=41.20/0.27
=152.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Biotest AG was 4300.00. The lowest was 20.60. And the median was 73.38.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Biotest AG Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Biotest AG's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotest AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (FRA:BIO) » Definitions » Cyclically Adjusted FCF per Share
Traded in Other Exchanges
Address
Landsteinerstrasse 5, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.